Journal of Cancer Research and Immuno-Oncology
Open Access

Overcoming Chemoresistance: Mechanisms and Novel Drug Targets

Pedro Max^{* *}Correspondence: Pedro Max, Department of Hematology and Oncology, Universidad Complutense de Madrid, Madrid, Spain, Email:

Author info »

Description

Chemotherapy remains a cornerstone of cancer treatment, especially for aggressive and metastatic tumors. Yet, its long-term success is frequently undermined by a major obstacle chemoresistance. Whether intrinsic or acquired, resistance to chemotherapy reduces treatment efficacy, leads to disease relapse, and limits patient survival. While researchers have uncovered many of the biological underpinnings of chemoresistance, translating this knowledge into effective, targeted interventions remains one of oncology's most urgent challenges. To advance cancer care, we must move beyond conventional drug development and embrace strategies that address resistance at its molecular roots.

The biology of resistance tumor survival strategies

Chemoresistance is not a single process but rather a multifaceted phenomenon driven by complex cellular adaptations. One of the most common mechanisms involves efflux pumps, such as P-glycoprotein (P-gp), which actively expel drugs from cancer cells. These ATP-Binding Cassette (ABC) transporters lower intracellular drug concentrations and render chemotherapy ineffective. Efflux pump overexpression has been documented in various cancers, including breast, colon, and ovarian.

Another well-documented mechanism is enhanced DNA damage repair. Many chemotherapy agents work by inducing DNA damage, which triggers cell death. Tumors that upregulate repair pathways like Homologous Recombination (HR) or Non-Homologous End Joining (NHEJ) can neutralize this damage and survive. For example, ovarian cancers with mutations are initially sensitive to platinum-based drugs but often develop resistance through secondary mutations that restore function.

Apoptosis evasion is also central to chemoresistance. Cancer cells may downregulate pro-apoptotic proteins (like Bax) or upregulate anti-apoptotic factors (such as Bcl-2 or survivin), allowing them to evade cell death even in the presence of cytotoxic drugs.

The Tumor Micro Environment (TME) contributes significantly to resistance. Hypoxic conditions, acidic pH, immune suppression, and stromal cell interactions can protect cancer cells from drug-induced stress. Cancer-Associated Fibroblasts (CAFs), for instance, secrete growth factors and cytokines that activate survival pathways in tumor cells. Similarly, immune cells within the TME can foster inflammation-driven resistance by supporting tumor growth and suppressing immune attack.

In solid tumors, drug penetration barriers and heterogeneity further complicate treatment. Dense extracellular matrices, poor vascularization, and high interstitial pressure reduce drug delivery. Meanwhile, genetically and phenotypically diverse cancer cell subpopulations respond differently to therapy, allowing resistant clones to expand after treatment.

The complexity of chemoresistance requires equally sophisticated solutions. One emerging strategy involves inhibiting drug efflux mechanisms. Several P-gp inhibitors have been tested in clinical trials, though early efforts were hindered by toxicity and lack of specificity. Newer-generation inhibitors with better pharmacokinetics and fewer side effects may offer renewed promise when combined with standard chemotherapy.

Targeting DNA repair pathways has also shown potential. PARP inhibitors such as olaparib have demonstrated efficacy in tumors with defective homologous recombination. These agents exploit synthetic lethality by blocking alternative repair pathways and pushing cancer cells toward lethal DNA damage accumulation. Efforts are underway to extend these strategies to a aggressive mutant tumors with distinct genetic and cellular characteristics.

Modulating apoptosis regulators is another compelling direction. Drugs that inhibit anti-apoptotic proteins, like the Bcl-2 inhibitor venetoclax, have already been approved for hematologic malignancies. Combining these agents with chemotherapy could help re-sensitize resistant tumors to treatment. BH3 mimetics, which restore the apoptotic machinery, are currently in various stages of clinical testing.

The tumor microenvironment offers additional therapeutic targets. Inhibiting stromal signaling pathways reprogramming immune cells, or disrupting extracellular matrix components may improve drug delivery and enhance sensitivity to chemotherapy. Immune checkpoint inhibitors have already shown the ability to reverse resistance in some cancers when used alongside conventional treatment.

Recent interest has also focused on non-coding RNAs as mediators of resistance. MicroRNAs (miRNAs) and long noncoding RNAs (lncRNAs) can regulate gene expression involved in drug metabolism, apoptosis, and repair. Therapeutically modulating these RNA molecules may offer a new layer of control over chemoresistant tumors.

Drug repurposing and combination therapies are gaining traction as cost-effective and efficient ways to overcome resistance. For example, using metformin or statins common medications with known safety profiles in combination with chemotherapy has demonstrated anti-resistance effects in preclinical studies. Similarly, combining chemotherapy with targeted agents or epigenetic modulators (like HDAC inhibitors) can reduce the likelihood of resistance development.

Technological advancements such as single-cell sequencing, organoids, and patient-derived xenografts are enhancing our understanding of resistance at the individual tumor level. These platforms enable researchers to model tumor evolution in response to drugs and identify novel vulnerabilities.

Conclusion

Chemoresistance remains one of the most formidable barriers in oncology. It is not a static phenomenon but a dynamic interplay of genetic mutations, cellular plasticity, and environmental cues. Overcoming it requires more than just developing stronger chemotherapy it calls for an integrated, precision-based approach that considers each tumor’s unique biology. 

The path forward involves combining conventional therapies with targeted agents, immune modulators, and biomarker-driven strategies. As we gain a deeper understanding of resistance mechanisms, we move closer to the goal of truly personalized cancer treatment one that anticipates resistance before it arises and adapts in real time.

Cancer may be relentless, but so too is scientific progress. By staying focused on the molecular drivers of resistance and translating discoveries into actionable treatments, we can make chemotherapy more effective, durable, and equitable for patients around the world.